ARTICLE SUMMARY:
The post-COVID-19 medtech industry continues to be a difficult space for both investors and entrepreneurs, but support for innovation is still available for companies that can navigate the challenges of early commercialization and reimbursement, according to the presenters at the Transcatheter Cardiovascular Therapeutics conference in Washington, DC.
The 2024 MedTech Innovation Forum at the Transcatheter Cardiovascular Therapeutics conference in Washington, DC, featured a lively discussion among industry veterans on the biggest challenges facing medtech innovators in the coming years. [Pictured above: Moderators Andrew Cleeland and Amr Salahieh.]
